The contribution of hematopoietic stem cells to beta-cell replacement

Valeria Sordi, Lorenzo Piemonti

Research output: Contribution to journalArticlepeer-review


Hemopoietic stem cells (HSCs) are commonly used for curing malignant and nonmalignant hematopoiesis disorders. In recent years, HSC potential giving rise to multilineage progeny has been reported. This issue, together with their availability and number, has made them ideal candidates for β-cell replacement in diabetic patients. HSC capacity to differentiate to insulin-producing cells has been at the center of debate for the past 5 years and it now seems that their role could more likely be that of helper cells able to facilitate survival or stimulate proliferation of endogenous β cells. In addition, clinical studies are ongoing about the possible use of HSCs to stop autoimmune destruction at the onset of diabetes or to induce tolerance through microchimerism in pancreatic islet transplantation.

Original languageEnglish
Pages (from-to)119-124
Number of pages6
JournalCurrent Diabetes Reports
Issue number2
Publication statusPublished - 2009

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine


Dive into the research topics of 'The contribution of hematopoietic stem cells to beta-cell replacement'. Together they form a unique fingerprint.

Cite this